Greedy Insider
Cue Biopharma, Inc. (CUE) Insider Trades and Scores
Cue Biopharma, Inc. (CUE) insider trades: since Dec 30, 2025, Greedy Insider recorded 6 open-market buys and 15 sales on Form 4 from 4 insiders. The strongest recent filing scored 84 (Strong).
Who bought and who sold
Across the last 21 scoreable Form 4 transactions in CUE, 6 were open-market purchases and 15 were sales. The table lists the most recent filings with each one's Greediness Score, so the structurally unusual trades are easy to spot first.
| Insider | Role | Type | Shares | Date | Score | ||
|---|---|---|---|---|---|---|---|
| Lin Shao-Lee | CEO | Sell | 1087.0 | 30490.35 | 2026-10-12 | 58 | View |
| Meluzio Michael Vincent | VP, Prin. Accounting Officer | Sell | 1144.0 | 32089.2 | 2026-10-12 | 65 | View |
| Lin Shao-Lee | CEO | Sell | 10000.0 | 275000.0 | 2026-10-12 | 74 | View |
| Ray Sumita | Chief Legal Compliance Officer | Sell | 1844.0 | 51724.2 | 2026-10-12 | 73 | View |
| Lin Shao-Lee | CEO | Sell | 5423.0 | 147451.38 | 2026-08-13 | 66 | View |
| Lin Shao-Lee | CEO | Sell | 2375.0 | 66761.25 | 2026-08-13 | 60 | View |
| Ray Sumita | Chief Legal Compliance Officer | Sell | 4.0 | 124.52 | 2026-08-13 | 66 | View |
| Meluzio Michael Vincent | VP, Prin. Accounting Officer | Sell | 1519.0 | 44613.03 | 2026-08-13 | 67 | View |
| Ray Sumita | Chief Legal Compliance Officer | Sell | 6442.0 | 195514.7 | 2026-08-13 | 82 | View |
| Ray Sumita | Chief Legal Compliance Officer | Sell | 2383.0 | 69988.71 | 2026-08-13 | 75 | View |
The strongest recent filing
Lin Shao-Lee (CEO) sold 34,225 shares of Cue Biopharma, Inc. on Aug 12, 2026, a filing that scored 84 (Strong). It scored Strong because a senior insider was trading and it was direct personal ownership. The score describes the filing, not future returns. This is not investment advice.
Cluster activity
A cluster buy is present: 3 insiders (Lin Shao-Lee, Ray Sumita, Meluzio Michael Vincent) traded CUE the same direction within a 7-day window. Shared conviction is a stronger structural signal than a lone trade.
How this compares with Cue Biopharma, Inc.'s own history
Open-market buys make up 29% of the 21 scoreable CUE transactions on record between Dec 30, 2025 and Oct 12, 2026. Comparing a filing with the company's own buy/sell mix is how you tell a routine disposal from an unusual accumulation.
Methodology and sources
Scores come from six published, user-adjustable factors (insider role, cluster activity, trade size versus the insider's own history, position impact, filing urgency, and direct versus indirect ownership). The score describes the filing, not future returns. This is not investment advice.
Key facts
- Scoreable Form 4 transactions on record: 21
- Open-market buys: 6
- Sales: 15
- Distinct insiders: 4
- Strongest recent Greediness Score: 84 (Strong)
Primary sources
Related
- Strongest filing
- CUE in the live feed
- How the Greediness Score works
- What is a cluster buy?
- Form 4 transaction codes
The score describes the filing, not future returns. This is not investment advice.